Mukund Paravasthu net worth and biography

Mukund Paravasthu Biography and Net Worth

COO of NovoCure

Mukund Paravasthu joined Novocure in 2020 and has served as its Chief Operating Officer (COO) since October 2024. He oversees product innovation and development, supply chain operations, warehousing and distribution, quality assurance and information technology operations. Mr. Paravasthu previously served as Novocure’s Senior Vice President of Product Development beginning in April 2022.

Before joining Novocure, Mr. Paravasthu held several leadership roles at Johnson & Johnson’s orthopedic franchise, DePuy Synthes. During his 13-year career there he served as Global Head of R&D for the Sports Medicine & Shoulder Reconstruction Business, Vice President of Advanced R&D and Vice President of Digital Solutions. Prior to joining Johnson & Johnson, he worked in research and development at Smith & Nephew.

Mr. Paravasthu holds a Master’s degree in Electrical Engineering from the University of Oklahoma and a Bachelors in Electrical and Electronics Engineering from Annamalai University, India.

What is Mukund Paravasthu's net worth?: The estimated net worth of Mukund Paravasthu is at least $66,451.91 as of November 1st, 2024. Mr. Paravasthu owns 3,503 shares of NovoCure stock worth more than $66,452 as of March 28th. This net worth approximation does not reflect any other investments that Mr. Paravasthu may own. Learn More about Mukund Paravasthu's net worth.
How do I contact Mukund Paravasthu?: The corporate mailing address for Mr. Paravasthu and other NovoCure executives is NO. 4 THE FORUM GRENVILLE STREET, ST. HELIER Y9, JE2 4UF. NovoCure can also be reached via phone at 441534756700 and via email at investorinfo@novocure.com. Learn More on Mukund Paravasthu's contact information.
Has Mukund Paravasthu been buying or selling shares of NovoCure?: Mukund Paravasthu has not been actively trading shares of NovoCure in the last ninety days. Most recently, Mukund Paravasthu sold 160 shares of the business's stock in a transaction on Friday, November 1st. The shares were sold at an average price of $15.88, for a transaction totalling $2,540.80. Following the completion of the sale, the chief operating officer now directly owns 3,503 shares of the company's stock, valued at $55,627.64. Learn More on Mukund Paravasthu's trading history.
Who are NovoCure's active insiders?: NovoCure's insider roster includes Michael Ambrogi (COO), Ely Benaim (Insider), Ashley Cordova (CFO), Asaf Danziger (CEO), William Doyle (Executive Chairman), Wilhelmus Groenhuysen (COO), Jeryl Hilleman (Director), Frank Leonard (Insider), Gabriel Leung (Director), Todd Longsworth (General Counsel), Martin Madden (Director), Mukund Paravasthu (COO), Michael Puri (Insider), Pritesh Shah (Insider), William Vernon (Director), and Uri Weinberg (Insider). Learn More on NovoCure's active insiders.
Are insiders buying or selling shares of NovoCure?: During the last twelve months, insiders at the medical equipment provider sold shares 5 times. They sold a total of 3,220 shares worth more than $61,749.10. The most recent insider tranaction occured on November, 1st when EVP Frank X Leonard sold 598 shares worth more than $9,532.12. Insiders at NovoCure own 6.3% of the company. Learn More about insider trades at NovoCure.
Information on this page was last updated on 11/1/2024.

Mukund Paravasthu Insider Trading History at NovoCure

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
11/1/2024	Sell	160	$15.88	$2,540.80	3,503

Mukund Paravasthu Buying and Selling Activity at NovoCure

NovoCure Company Overview

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.

Today's Range

Now: $18.97

$18.31

$19.06

50 Day Range

MA: $21.87

$18.19

$27.02

2 Week Range

Now: $18.97

$11.70

$34.13

Volume

490,446 shs

Average Volume

1,191,815 shs

Market Capitalization

$2.09 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.63